Cipla trades higher on the bourses

07 Sep 2015 Evaluate

Cipla is currently trading at Rs. 651.50, up by 2.10 points or 0.32% from its previous closing of Rs. 649.40 on the BSE.

The scrip opened at Rs. 655.00 and has touched a high and low of Rs. 662.00 and Rs. 650.00 respectively. So far 119110 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 752.45 on 10-Mar-2015 and a 52 week low of Rs. 546.00 on 05-Sep-2014.

Last one week high and low of the scrip stood at Rs. 688.75 and Rs. 644.85 respectively. The current market cap of the company is Rs. 52430.70 crore.

The promoters holding in the company stood at 36.79% while Institutions and Non-Institutions held 34.30% and 26.60% respectively.

Cipla’s UK arm - Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc. The transaction being subject to certain closing conditions is valued at $550 million and will be an all cash transaction. The combined revenue from these transactions is over $200 million for the year ended Dec 2014 and over $225 million in LTM June 2015. This acquisition, which is the second landmark acquisition in Cipla’s 80 years of history, will give the company scale in the US generics market through a wide range of product portfolio in CNS, CVS, anti-infectives, diabetes as well as other value added generics.

InvaGen offers a large capacity manufacturing base in Hauppauge, NY and a skilled US-based R&D organization, Cipla’s first such presence in the US. The acquisition of InvaGen pharmaceuticals also provides Cipla with about 40 approved ANDAs, 32 marketed products, and 30 pipeline products which are expected to be approved over the next 4 years.

The acquisition of Exelan Pharmaceuticals provides Cipla access to the government and institutional market in the US through Exelan’s deep expertise, engagement and experienced management team in the business.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

 

 

Cipla Share Price

1510.90 19.50 (1.31%)
31-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.75
Dr. Reddys Lab 1271.05
Cipla 1510.90
Zydus Lifesciences 914.65
Lupin 2112.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×